MCET — Multicell Technologies Share Price
Last trade - 00:00- $0.01m
- -$1.54m
- $0.05m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.01 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -33.24% | ||
Financial Summary
| Year End 30th Nov | Unit | 2010 | 2011 | 2012 | 2013 | 2014 | 2015E | 2016E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.1 | 0.05 | 0.05 | 0.05 | 0.05 | n/a | n/a | -22.31% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company. The Company and its subsidiaries are developing therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer and interventional cardiology, and peripheral vessel applications. The Company's portfolio of lead drug candidates is in various stages of discovery optimization, and preclinical and clinical development, and includes MCT-125, MCT-465, MCT-475 and MCT-485. MCT-125 is a Phase II therapeutic candidate for the treatment of primary multiple sclerosis-related fatigue. MCT-465 is a preclinical synthetic double-stranded ribonucleic acid (dsRNA) therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers. MCT-475 is a discovery-stage antibody therapeutic candidate used in combination with dsRNA for the treatment of solid tumor cancers. MCT-485 is a discovery-stage dsRNA therapeutic candidate for the treatment of certain cancers.
Directors
- W. Gerald Newmin CHM (82)
- Stephen Chang DRC (60)
- Grant Miller DRC (64)
- Thomas Page IND (86)
- Edward Sigmond IND (61)
- Last Annual
- November 30th, 2014
- Last Interim
- August 31st, 2015
- Incorporated
- April 28th, 1970
- Public Since
- June 16th, 1994
- No. of Employees
- 2
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 5,000,948,700
- Address
- 68 Cumberland Street, Suite 301, WOONSOCKET, 02865
- Web
- http://www.multicelltech.com/
- Phone
- +1 4017620045
- Auditors
- Eide Bailly, L.L.P.
Upcoming Events for MCET
Similar to MCET
Acorda Therapeutics
Pink Sheets on Nasdaq
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
FAQ
As of Today at 19:15 UTC, shares in Multicell Technologies are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in Multicell Technologies last closed at $0.00 and the price had moved by over the past 365 days. In terms of relative price strength the Multicell Technologies share price has underperformed the S&P500 Index by -11.77% over the past year.
There is no consensus recommendation for this security.
Multicell Technologies does not currently pay a dividend.
Multicell Technologies does not currently pay a dividend.
Multicell Technologies does not currently pay a dividend.
To buy shares in Multicell Technologies you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in Multicell Technologies had a market capitalisation of $0.01m.
Here are the trading details for Multicell Technologies:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: MCET
Based on an overall assessment of its quality, value and momentum Multicell Technologies is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Multicell Technologies. Over the past six months, its share price has underperformed the S&P500 Index by -13.79%.
As of the last closing price of $0.00, shares in Multicell Technologies were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Multicell Technologies PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Multicell Technologies' management team is headed by:
- W. Gerald Newmin - CHM
- Stephen Chang - DRC
- Grant Miller - DRC
- Thomas Page - IND
- Edward Sigmond - IND